uniQure N.V./CSL Limited’s Hemgenix (tranacogene dezaparvovec-drlb) has been approved for the treatment of adults with moderately severe to severe hemophilia B by the US Food and Drug Administration, making it the first gene therapy for the rare bleeding disorder and the most expensive drug to date.
The Australian firm revealed the treatment would cost $3.5m in the US, edging past the $3m price tag for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?